NEWS IN PEDIATRIC GASTROENTEROLOGY PHARMACOLOGY
Teduglutide in pediatric short bowel syndrome
Teresa Capriati1, Antonella Lezo2, Paolo Lionetti3, Maria Immacolata Spagnuolo4, Paolo Gandullia5, Lorenzo D’antiga6, Paola Roggero7, Antonella Diamanti1
1Gastroenterology and Nutritional Rehabilitation Unit, Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio 4, Rome, Italy. 2Dietetics and Clinical Nutrition Unit, Children’s Hospital Regina Margherita, Città della Salute e della Scienza Torino, Piazza Polonia 94, Turin, Italy. 3Department NEUROFARBA. University of Florence. Meyer Children’s Hospital, viale Gaetano Pieraccini 24, Florence, Italy. 4Department of Translational Medical Sciences, University Federico of Naples, V S Pansini 5, Naples, Italy. 5Pediatric Gastroenterology and Endoscopy, IRCCS G.Gaslini Institute, via Gerolamo Gaslini 5, Genoa. 6Paediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII, Piazza OMS 1, Bergamo, Italy. 7Neonatal Intensive Care Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, Milan, Italy. Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.
Subcutaneous teduglutide (Ted), a glucagon-like peptide-2 analogue, was approved in January 2021 in Italy for the short bowel syndrome (SBS) treatment in stable patients aged ≥1 year, after a period of postsurgical intestinal adaptation. Ted seems to facilitate intestinal adaptation. It has had a good spread in adulthood, while pediatric data are still scarce. This review summarizes the current knowledge about Ted. An Italian consensus is being drawn up on the use of Ted in pediatrics.